Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending September 2024 and Fiscal Year Ending March 2025
May 13, 2024 at 02:00 am EDT
Share
Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the period ending September 2024 and fiscal year ending March 2025. For the period, the company expected sales of JPY 99,000 million, Operating profit of JPY 13,600 million, Profit attributable to owners of parent of JPY 22,000 million, Basic earnings per share of JPY 167.42.
For the year, the company expected sales of JPY 202,000 million, Operating profit of JPY 26,000 million, Profit attributable to owners of parent of JPY 30,000 million, Basic earnings per share of JPY 228.30.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
SAWAI GROUP HOLDINGS CO., LTD. 
